Holen Sie sich die Stockscreener-App
5.21
1.56%
0.08
Vorhandelsmarkt:
5.21
Protara Therapeutics Inc Aktie (TARA) Neueste Nachrichten
Protara's experimental bladder cancer drug shows encouraging results - MSN
Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS
Published on: 2026-04-14 02:30:36 - baoquankhu1.vn
Exit Recap: Can Protara Therapeutics Inc beat the S P 5002026 Institutional & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Retail Trends: Can Protara Therapeutics Inc beat the S P 5002026 Institutional Moves & Low Drawdown Momentum Ideas - baoquankhu1.vn
Analyst Upgrade: Will Protara Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Insider Sell: Jacqueline Zummo Sells Shares of Protara Therapeutics Inc (TARA) - GuruFocus
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock - Investing.com Canada
Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) R&D chief sells 1,134 shares under 10b5-1 plan - Stock Titan
Quarterly Risk: Is Protara Therapeutics Inc trading at a discountBuy Signal & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Sentiment Review: Whats Protara Therapeutics Incs historical returnWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Investor Mood: Can Protara Therapeutics Inc deliver consistent EPS growth2026 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn
Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Th - GuruFocus
Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock - MarketBeat
Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan - Stock Titan
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Risk Hedge: What is the target price for Protara Therapeutics Inc stock2026 Trading Recap & Momentum Based Trading Ideas - baoquankhu1.vn
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results - TipRanks
Protara Therapeutics reports six-month response rate in bladder cancer trial - Investing.com
Protara Therapeutics reports six-month response rate in bladder cancer trial By Investing.com - Investing.com South Africa
Protara reports 68.0% six-month CR rate in 25 BCG-unresponsive patients, warrants exercisable through June 29, 2026 - TradingView
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics Inc Stock: Clinical Progress and Strategic Outlook for Investors in Tearnatin a - AD HOC NEWS
Profit Recap: Is Protara Therapeutics Inc still a buy after recent gains2026 Breakouts & Breakdowns & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-03-26 17:09:27 - baoquankhu1.vn
Aug Swings: Can Protara Therapeutics Inc deliver consistent dividends2026 Chart Watch & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Protara Therapeutics Inc stock faces volatility amid clinical pipeline updates and biotech sector pr - AD HOC NEWS
Form 144 Protara Therapeutics For: 6 March By Investing.com - Investing.com Australia
Aug Ideas: What is the Moat Score of Protara Therapeutics IncMarket Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Sentiment Recap: Whats the profit margin of Protara Therapeutics IncGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February - MarketBeat
Equities Analysts Offer Predictions for TARA Q1 Earnings - MarketBeat
Lifesci Capital Issues Optimistic Estimate for TARA Earnings - MarketBeat
Protara Therapeutics (TARA) Receives a Buy from Oppenheimer - The Globe and Mail
FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat
Analysts’ Top Healthcare Picks: Protara Therapeutics (TARA), Viridian Therapeutics (VRDN) - The Globe and Mail
Published on: 2026-03-12 04:53:12 - baoquankhu1.vn
Cowen Maintains Buy on Protara Therapeutics (TARA) March 10, 2026 - Meyka
TD Cowen reiterates Protara Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TARA Advances Clinical Programs with Key Milestones Ahead - GuruFocus
TARA Secures Financial Stability with $197.9 Million Cash Reserves - GuruFocus
Protara Therapeutics (NASDAQ:TARA) Releases Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Protara Therapeutics (NASDAQ: TARA) advances TARA-002 and IV Choline into registrational-stage trials - Stock Titan
Protara Therapeutics 2025 Annual Report: Pipeline, Regulatory Strategy, and Commercialization Plans for Cancer and Rare Disease Therapies - Minichart
Protara 10-K: Net loss $57.4M, EPS $(1.34); operating loss widens to $64.5M - TradingView
Protara Therapeutics reports $197.9M cash; Q4 net loss $17.3M, FY loss $57.4M - TradingView
Protara Therapeutics: Q4 Earnings Snapshot - marketscreener.com
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):